ERBB2 and breast cancer: Next, we examined the clinicopathological variables between AR+PDEF+ and others in the 100 ER-negative BC specimens and found that AR+PDEF+ was associated with pTNM stage (P = 0.047) and HER2 expression (P = 0.039) (Table 1).